Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Prepaid Assets (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Prepaid Assets for 8 consecutive years, with $26.5 million as the latest value for Q1 2026.

  • For Q1 2026, Prepaid Assets rose 48.88% year-over-year to $26.5 million; the TTM value through Mar 2026 reached $26.5 million, up 48.88%, while the annual FY2025 figure was $22.9 million, 6.57% up from the prior year.
  • Prepaid Assets hit $26.5 million in Q1 2026 for Kymera Therapeutics, up from $22.9 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $26.5 million in Q1 2026 and bottomed at $8.1 million in Q2 2022.
  • Average Prepaid Assets over 5 years is $15.7 million, with a median of $14.1 million recorded in 2023.
  • On a YoY basis, Prepaid Assets climbed as much as 84.38% in 2024 and fell as far as 0.32% in 2024.
  • Kymera Therapeutics' Prepaid Assets stood at $9.7 million in 2022, then grew by 20.19% to $11.7 million in 2023, then skyrocketed by 84.38% to $21.5 million in 2024, then grew by 6.57% to $22.9 million in 2025, then grew by 15.54% to $26.5 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $26.5 million, $22.9 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.